Get the Full Story, Without the Noise.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Eurovision
Artificial Intelligence
Social Media
Soccer
Real Estate
Sanctions
Inflation
Donald Trump
Baseball
Vladimir Putin
NHS
Infrastructure
Published • loading... • Updated

Japan’s MHLW approves Sarepta's gene therapy for DMD

Summary by Pharmaceutical-technology.com
Japan’s MHLW has approved Sarepta Therapeutics’ gene therapy Elevidys for treating Duchenne muscular dystrophy (DMD)
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

3 Articles

All
Left
Center
Right
GeneOnline NewsGeneOnline News

Japan Approves Sarepta Therapeutics’ Elevidys Gene Therapy for Duchenne Muscular Dystrophy

Japan’s Ministry of Health, Labour and Welfare (M […] The post Japan Approves Sarepta Therapeutics’ Elevidys Gene Therapy for Duchenne Muscular Dystrophy first appeared on GeneOnline News. The post Japan Approves Sarepta Therapeutics’ Elevidys Gene Therapy for Duchenne Muscular Dystrophy appeared first on GeneOnline News.

Read Full Article
pharmaceutical-technology.compharmaceutical-technology.com

Japan’s MHLW approves Sarepta's gene therapy for DMD

Japan’s MHLW has approved Sarepta Therapeutics’ gene therapy Elevidys for treating Duchenne muscular dystrophy (DMD)

Read Full Article
熊本日日新聞社熊本日日新聞社

Drug for muscular dystrophy approved under certain conditions for children with genes in their bodies (Kyodo News)

On the 13th, the Ministry of Health, Labor and Welfare gave conditional approval for the manufacture and sale of Chugai Pharmaceutical's gene therapy drug "Elevisis" for Duchenne muscular dystrophy, a condition that gradually causes muscle loss, for a period of three years. It is intended for patients aged between three and eight who are able to walk. The drug is manufactured by Swiss-based

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

熊本日日新聞社 broke the news in on Tuesday, May 13, 2025.
Sources are mostly out of (0)

Similar News Topics

Welfare

Welfare

Japan

Japan

News
For You
SearchBlindspotLocal